Selected Publications

Wang L, Rahimi Larki N, Dobkin J, Salgado S, Ahmad N, Kaplan DE, Yang W, Yang YX.: A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With Acute Pancreatitis. Pancreas 53(3): e254-e259, 2024.

Khan N, Sundararajan R, Patel M, Trivedi C, Yang YX.: Effectiveness of Tofacitinib in Patients With Ulcerative Colitis: A Nationwide Veterans Administration Cohort Study. Am J Gastroenterology 2024 Notes: In press.

Lam R, Hwang WT, Chennareddy S, Boursi B, Yang YX: Exogenous Insulin Therapy Is Associated with the Risk of Advanced Colorectal Adenoma in Patients with Diabetes Mellitus. Dig Dis Sci 2024 Notes: In Press.

Mezzacappa C, Larki NR, Skanderson M, Park LS, Brandt C, Hauser RG, Justice A, Yang YX, Wang L.: Development and Validation of Case-Finding Algorithms to Identify Pancreatic Cancer in the Veterans Health Administration. Dig Dis Sci 69(4): 1507-1513, 2024.

Kurlander JE, Laine L, Kim HM, Roberts CB, Saffar D, Myers A, Holleman R, Gao Y, Shank M, Nelson R, Forman J, Helfrich CD, Krein SL, Saini SD, Yang YX: Impact of large scale, multicomponent intervention to reduce proton pump inhibitor overuse in integrated healthcare system: difference-in-difference study. BMJ 385: e076484, 2024.

Wang L, Grimshaw AA, Mezzacappa C, Rahimi Larki N, Yang YX, Justice AC: Do polygenic risk scores add to clinical data in predicting pancreatic cancer? a scoping review. Cancer Epidemiol Biomarkers Prev August 2023 Notes: In press.

Hernandez-Con P, Shults J, Willis AW, Yang YX: Dopamine agonists and risk of lung cancer in patients with restless legs syndrome. Pharmacoepidemiol Drug Saf 32(7): 726-734, Jul 2023.

Brown TJ, Mamtani R, Gimotty PA, Karasic TB, Yang YX.: Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis. J Cancer Res Clin Oncol 149(6): 2345-2354, Jun 2023.

Thanawala SU, Kaplan DE, Falk GW, Beveridge CA, Schaubel D, Serper M, Yang YX.: Antibiotic Exposure is Associated With a Risk of Esophageal Adenocarcinoma. Clin Gastroenterol Hepatol S1542-3565(23): 00220-3, March 2023.

Tompkins WP, Hwang WT, Yang YX, Singh A, Ciunci C, D'Avella C, Aggarwal C, Cohen RB, Langer CJ, Mamtani R, Marmarelis ME.: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens. Clin Lung Cancer 24(6): 558-562, 2023.